Evaluation of a commercially available apparatus for measuring the acute phase protein serum amyloid A in horses.

This study evaluates the reliability of a commercially available test for the acute phase protein serum amyloid A (SAA) in horses, a protein level often measured in the diagnosis of inflammatory diseases. The research found that the test was mostly accurate, if slightly underestimating SAA levels compared to a previously validated assay.

Reliability of Immunoturbidometric Assay

The researchers conducted an analysis of a commercially available test known as an immunoturbidometric assay to measure the level of serum amyloid A (SAA), an acute phase protein in horses. Acute phase proteins are molecules produced by the liver in response to inflammation, injury, or disease. SAA, in particular, is known to significantly increase in response to inflammation or infection, making it a useful biomarker for health evaluation.

• The evaluation was performed by comparing the results of this assay to a previously validated assay. This serves as a standard or control, allowing the researchers to assess the reliability and accuracy of the new apparatus.
• The performance of the assay was further evaluated under real clinical conditions where the concentration of SAA was tested among a variety of horses: those who were clinically healthy, those with inflammatory diseases, and those with non-inflammatory diseases. This provided a range of SAA concentrations for a more comprehensive appraisal of the assay’s reliability.

Test’s Accuracy and Variation Coefficients

The assay was examined for its precision and accuracy.

• In pools of serum with low and high concentrations of SAA, the intra-assay coefficients of variation (COV), representing the variability of results within the assay itself, were found to be 11.7 per cent and 4.6 percent respectively.
• The interassay COVs, demonstrating variability across separate runs of the test, were 9.1 per cent and 5.6 per cent, respectively. These results suggest a generally good repeatability of the assay.
• However, the researchers noticed slight inaccuracies in the assay’s results. Despite these, the inaccuracies were deemed negligible when compared to the overall range of the SAA response, indicating that these errors were relatively unimportant in the context of the test’s overall performance.

Systematic Underestimation and Detection Ability

The commercially available assay demonstrated a systematic underestimation in the levels of SAA compared to the validated assay.

• Although the new assay consistently reported lower levels of SAA than the validated test, this underestimation did not hinder its ability to distinguish between the healthy and diseased horses. This confirmed its effective ability to detect abnormal levels of SAA, despite showing a slight bias towards lower values.